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Abstract
The potential role of Chlamydia pneumoniae 
infection in the progression of atherosclerosis
Eui Young Choi
Brain Korea 21 Project for Medical Science
The Graduate School, Yonsei University
(Directed by Professor Hyun-Seung Kim)
Background: Chronic Chlamydia pneumoniae infection has been implicated 
as important etiologic factor of atherosclerosis, in particular coronary artery 
disease (CAD). Some experimental evidence links C pneumoniae  with the 
induction of matrix metalloproteinases (MMPs). However, the regulation of 
MMPs by C pneumoniae within atheroma remains unclear. A recent study 
suggested that an EMMPRIN/MT1-MMP system exists that induces and 
activates MMP, and that is upregulated in the failing human left ventricle.  In 
the present study, we examined the seropositive rate of C pneumoniae 
antibody in CAD patients, and investigated the relationship between C 
pneumoniae and the expression of MMPs in human atherosclerotic specimens. 
Furthermore, we investigated an EMMPRIN/MT1-MMP system that 
induces/activates MMPs in C pneumoniae  infected atherosclerotic tissues and 
examined its potential role in the progression of atherosclerosis.  
Materials and methods: We tested the prevalence of C pneumoniae 
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infection in CAD patients (n=391) and controls (n=97) by serologic study. In 
the present study, we evaluated the relationship between C pneumoniae and 
atherosclerosis by using a seroepidemiologic study. In addition, we performed  
histopathological and in vitro analysis in human atherosclerotic aortic and 
carotid artery tissues obtained from patients seropositive to C pneumoniae 
(n=20), by using antibodies to  C pneumoniae, EMMPRIN/MT1-MMP, 
MMP-2, MMP-9, COX-2 and TIMP-2.
Results: The seropositive rates of both anti-C pneumoniae IgG and IgA in 
the CAD patients were elevated in subgroups without conventional coronary 
risk factors compared with subgroups with conventional risk factors. 
Immunoreactivities of EMMPRIN, MT1-MMP, COX-2, MMP-2, and MMP-9 
were increased in the atherosclerotic plaque itself, predominantly in   
immunoreactive macrophages/foam cells to C pneumoniae. Furthermore MMP-2 
and MMP-9 zymographic activities were more increased in C pneumoniae 
infected atheromatous tissues compared with control tissues. Western blot for 
EMMPRIN, MMP-2 and TIMP-2 demonstrated that EMMPRIN, MMP-2 and 
TIMP-2 were detected more prominent in C pneumoniae infected atheromatous 
tissues compared with control tissues. 
Conclusion: These findings help to understand the potential role of C 
pneumo1)niae  in the progression of atherosclerosis. 
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
Key Words: atherosclerosis,  Chlamydia pneumoniae,  EMMPRIN, MMPs, 
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The potential role of Chlamydia pneumoniae 
infection in the progression of atherosclerosis
Eui Young Choi
Brain Korea 21 Project for Medical Science
The Graduate School, Yonsei University
(Directed by Professor Hyun-Seung Kim)
I.  Introduction
Several classic risk factors have been identified for the development and 
progression of atherosclerosis. and coronary artery disease (CAD). However, 
these factors may explain only the high prevalence of CAD in part1.    
Injury to a vessel wall and the associated inflammatory response are now 
generally recognized as essential components of atherogenesis. However, the 
stimuli that initiate and sustain the inflammatory process have not been fully 
identified. Infectious insult is a candidate trigger of immuno-inflammatory 
response, and might be a source of chronic local or systemic inflammation2. 
 Recently, substantial seroepidemiologic and some experimental evidence has 
linked Chlamydia pneumoniae (C pneumoniae) with the natural history of 
atherosclerosis3,4. However, the mechanisms by which this agent  affects 
atherogenesis and the progression of atherosclerosis remain poorly understood. 
C pneumoniae is an obligate, intracellular, Gram-negative bacterium and 
airborne infection with this agent, often chronic and asymptomatic, is prevalent 
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in the general population. Moreover, an antibody titer against C pneumoniae, 
detectable in 40% to 50% of the adult population, has been found to correlate 
positively with the occurrence of coronary artery disease5,6.  In the growth 
cycle of C pneumoniae  there are 2 morphologically and functionally distinct 
cell types: the infectious elementary body (EB) and the reproductive reticulate 
body (RB)7. Under some conditions, certain chlamydia can achieve a state of 
intracellular chronic, persistent infection in which they remain viable but 
metabolically quiescent and do not replicate. During such chronic, persistent 
infection C pneumoniae expresses basal levels of two major antigens: the 
major outer membrane protein (MOMP) and the heat shock protein 60 (HSP 
60; 60 stands for 60kDa).  Although C pneumoniae  can infect most  cells 
present in atheroma8,9,10,11, it localizes mainly  to macrophages/monocytes in the 
plaque. These lesional macrophages/monocytes can produce matrix 
metalloproteinases (MMPs)12, enzymes now accorded a major role in the 
degradation of the extracellular matrix of vascular tissue13.  Thus, 
macrophage/monocytes-derived MMPs may play a role in the vulnerability of 
plaque and consequent thrombosis, and ultimately the progression of 
atherosclerosis and the acute coronary events14.
 MMPs are a family of enzymes that, as a group, can degrade a wide 
variety of extracellular matrix components and have been implicated in normal 
tissue remodeling as well as in inflammatory processes, tumor invasion, and 
wound healing. Seventeen MMPs are expressed in vitro by a variety of 
vascular cells, including macrophages, smooth muscle cells, and endothelial 
cells15,16,17. Recently, Kol at al.18 reported that chlamydial HSP 60 derived from 
C trachomatis stimulate the expression of  tumor necrosis factor-α (TNF-α) 
and MMP-9 by mouse peritoneal macrophages and Kreula et al.19 reported that 
C pneumoniae  proteins induce the secretion of the 92-kDa gelatinase (MMP-9) 
by human monocyte derived macrophages.  However, it remains unclear 
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whether MMPs are regulated by C pneumonia  within atheromatous plaques 
and whether the upstream cellular and molecular mechanisms of local MMP 
induction/activation system exist associated with C pneumoniae. 
Recently, a tumor-derived protein, extracellular matrix metalloproteinase 
inducer (EMMPRIN), was found to induce the production of MMPs from 
stromal fibroblasts and to be crucial in tumor invasion20. In addition,  it has 
been reported that MMP-9 and EMMPRIN were increased in the LV 
myocardium of ischemic DCM(dilated cardiomyopathy) and nonischemic DCM21. 
Moreover Major et al.22 reported that EMMPRIN is induced upon monocyte 
differentiation and is expressed in human atheroma. EMMPRIN is a 58-kDa, 
membrane-bound protein that has been identified in both normal and diseased 
human tissue. It also known as basign or CD147, and is a glycoprotein, which 
is enriched on the surface of tumor cells, and which stimulates the production 
of several matrix metalloproteinases by adjacent stromal cells. The exposure of 
human fibroblasts to recombinant EMMPRIN causes the induction of MMP-1, 
MMP-2 and MMP-3, and basal expression of EMMPRIN has been reported in 
a number of tissue types, suggesting that this transmembrane protein has 
multiple roles23.
 In the present study, we evaluated the relationship between C pneumoniae  
and atherosclerosis seroepidemiologically.  To investigate the potential role of 
C pneumoniae in the progression of atherosclerosis, we performed  
histopathological and in vitro analyses in human atherosclerotic aortic and 
carotid artery tissues, obtained from patients who were found seropositive for 
C pneumoniae, by using antibodies to  C pneumoniae, EMMPRIN/MT1-MMP, 
MMP-2, TIMP-2 and MMP-9. The presence of the organism in atherosclerotic 
plaques has been investigated using various techniques such as 
immunohistochemistry (IHC), polymerase chain reaction (PCR), electron 
microscopy and isolation in tissue culture, but generally, IHC provides better 
- 6 -
evidence for C pneumoniae than PCR in that point it can directly show the 
protein expression and colocalization. Therefore, we tested immunoreactivity for 
C pneumoniae  and inflammatory mediators, such as,  MMP-2, and MMP-9, to 
determine whether they are colocalized to inflammatory cells in atheromatous 
plaque, and to determine  if C pneumoniae has some pathogenic role on 
atherosclerotic disease.  That is, if the vascular infection of C pneumoniae  can 
induce a chronic inflammatory reaction in host vascular tissue and activate 
inflammatory cells, some inflammatory mediators, such MMP-2 and MMP-9 
may show increased expression around macrophages, which have a key role in 
atherosclerosis, infected with C pneumoniae.  Furthermore, IHC of the 
EMMPRIN/MT1-MMP system, the upstream cellular and molecular 
mechanisms for a local MMP induction/activation system, was performed to 
investigate the potential role of C pneumoniae  in the  progression of 
atherosclerosis. 
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II.  Materials and Methods
1. Seroepidemiologic study
 Among the patients with  typical symptoms of angina and with positive 
results in non-invasive testing (EKG, Treadmill test) who visited Yong-Dong 
Severance Hospital, 391 patients who underwent coronary angiogram were 
included in this study. Among them, the patients who demonstrated luminal 
narrowing of more than 50% in at least one vessel were grouped into the 
disease group (Group I, n=254) and those patients who had normal coronary 
arteries or minimal lesion were grouped into the positive control group (Group 
II, n=137).  We also  studied healthy persons who had not experienced any 
symptoms related to coronary heart disease and had normal findings on 
noninvasive tests for coronary artery disease and these subjects were grouped 
into the negative control group (Group III, n=97). Serologic tests for 
anti-chlamydial Ig G and Ig A were performed using ELISA kit (Bioclonic 
Inc., Sydney, Australia). 
2.  Tissue preparation and histologic examination
 The study population  consisted of 20 patients with atherosclerotic aortic  
(5 patients) and carotid artery diseases (15 patients). All patients were 
seropositive to C pneumoniae either with Ig G or Ig A antibodies. Serologic 
test for anti-chlamydial Ig G and Ig A were performed using ELISA kit. For 
control studies, aorta specimens, from which atherosclerotic lesions including 
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fatty streak and plaque were excluded, were obtained from 5 patients who 
were surgically treated for traumatic aortic dissection with C pneumoniae 
seronegativity. 
  Immediately following the removal of the specimens, each was fixed with 
buffered 10% formalin in order to  maintain vascular morphologic integrity. To 
preserve the  integrity of the advantitia and perivascular tissues, the specimens 
were carefully removed in a segment along with adjacent tissues and rinsed 
with PBS (phosphate buffered saline). Each segment was embeded in paraffin 
and cut in 5 μm sections, which were then stained with hematoxylin-eosin 
(H&E). Sections of these tissues were also used for the immunohistochemical 
staining procedure.
3.  Immunohistochemical staining
  Mouse anti-C pneumoniae  monoclonal antibody (RR-402) (DAKO Inc., 
Carpenteria, CA, USA) and goat polyclonal antibodies against human MMP-2, 
MMP-9, COX-2 (cyclooxygenase-2), TIMP-2, MT1-MMP and EMMPRIN 
(Santa-Cruz Biothchnology Inc., Santa Cruz, CA, USA) were used as the 
primary antibodies for immunohistochemical staining.  To characterize the type 
of infected cells, HAM56 (monoclonal mouse anti-human macrophage) was 
used for the immunostaining of the tissue type of macrophage/mononuclear 
cell.  Anti-chlamydial antibody reacts with a major outer membrane protein 
(MOMP) of C pneumoniae and the immunogen is C pneumoniae  strain 
TW183. Peroxidase-conjugated secondary antibodies were used with  these 
primary antibodies. 
 The paraffin sections were deparaffinized and rehydrated and then the 
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sections are boiled with citric acid for 5 minutes in order to suppress 
nonspecific binding of the antibodies and to increase the exposure of antigens, 
and cooled at room temperature for 20 minutes. The sections were then treated 
with 0.3% H2O2 for 5 minutes to suppress endogenous peroxidase activity. 
After treatment  with PBS (pH=7.2-7.4) for 5 minutes and application of 1:5 
diluted anti-chlamydial primary antibodies (RR-402) and 1:100 diluted 
EMMPRIN, MT1-MMP, MMP-2, TIMP-2, MMP-9, COX-2 and HAM56 
primary anribodies, the sections were incubated in a moist chamber for 1 hour. 
After washing and bathing for 5 minutes by PBS, the biotinylated secondary 
antisera cocktail including goat anti-mouse and anti-rabbit IgG diluted 1:400 
was incubated on the slides for 15 minutes at room temperature in a moist 
chamber. The sections were then processed by the 
streptavidin-biotin-peroxidase complex method by use of the LSAB(+) kit 
(DAKO Inc. Carpenteria, CA, USA) and DAB solution (Research Genetics Inc., 
Huntsville, AL. USA) in order to produce a brown color at the site of 
reactivity. The sections were then counterstained with Mayer's hematoxylin.
4.  Western blot
 A 50μg proteins were subjected to 8-12% gradient SDS-PAGE gel and 
transferred to immunobilon-P membrane(Millipore, Bedford, MA, USA) at 12V 
for 1h. The membrane was blocked in 5% nonfat dry milk in TBST at 25。C 
for 1h. Proteins were detected using EMMPRIN, MMP-2, TIMP-2: 5 μg/mL 
and secondary antibody (human rabbit/mouse IgG, horseradish 
peroxidase-conjugated, Amersham) was used at 1:2000 dilution. Signals were 
detected with an ECL kit (Amersham), and exposed to X-ray film (Kodak, 
- 10 -
Rochester, NY, USA). 
5.  Gelatine zymography
 Enzymatic activities of MMP-2 and MMP-9 were investigated using 
zymographic analysis. The protein content of the cultured medium was by 
the method of Bradford, using serum albumin as standard. 50μg proteins of 
culture medium from HUVECs and CASMCs with leptin treatment (10mg to 
40 mg) and control were mixed with 5 x sample buffer and loaded on a 11% 
SDS-PAGE gel containing with 0.1% gelatin for electrophoresis under 4。C cold 
room. Gels were reacted with collagenase buffer for 16h at 37。C, stained with 
0.25% coomassie brilliant blue, and destained with 30% isopropanol in 10% 
acetic acid to visualize the MMP bands.
6.  Statistical analysis
 
We used SPSSWIN 8.0 software for the statistical analysis and the 
seropositive rate of each group was compared by Chi-square test for 
univariate analysis and logistic regression for multivariate analysis. P<0.05 was 
regarded as a statistically significant difference.
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III.  Results
1. Seroepidemiologic study
 A total of 488 persons were included in this seroepidemiologic study for 
anti-Chlamydia pneumoniae  Ig G and Ig A (group I: 254 in the disease,  
group II: 137 in the positive control, group III: 97 in the negative control). The 
simultaneous seropositive rates of both Ig G and Ig A were 56.7%, 61.3%, and 
43.3% in Group I, II and III, respectively, and there was a significant difference 
between group I and III (p=0.033, OR=1.71 (95% CI; 1.07-2.75)). In subgrouping 
by conventional risk factors, the seropositive rates of both IgG and IgA in 
group I and group III, respectively, were 52.1% and 31.0% (p=0.035, OR=2.4) in 
females, 54.4% and 31.4% (p=0.008, OR=2.6) in non-smokers, 61.5% and 42.7% 
(p=0.013, OR=2.1) in patients with normal blood pressure, 59.9% and 40.2% 
(p=0.004, OR=2.2) in non-diabetes, 58.6% and 41.5% (p=0.016, OR=2.2) in 
patients with normal cholesterol level (<240 mg/dl), 58.1% and 42.0% (p=0.038, 
OR=1.9) in patients with high HDL-cholesterol level (≥35 mg/dl), and 58.3% 
and 40.7% (p=0.018, OR=2.0) in patients with low LDL-cholesterol level (<160 
mg/dl). By multivariate analysis using Logistic regression, a statistical 
significance was noticed in females (p=0.012, OR=5.2 (95% CI; 1.4-18.6)) and 
non-smokers (p=0.012, OR=3.9 (95% CI; 1.3-11.0)) (Tables 1 and 2).  
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2.  Histopathologic analysis
The sections of aorta  taken from traumatic dissection as the normal 
control showed no histological evidence of atherosclerosis, except for minimal 
intimal thickening, and showed normal patterns of elastic media, and no 
immunoreactivity to C pneumoniae and trace immunoreactivities for MMP-2, 
MMP-9, TIMP-2 and EMMPRIN in the minimal thickened intima, and no 
immunoreactivity in the media (Fig.1).
 In contrast to the control group, the 20 case-specimens showed a 
thickened intima from necrosis and a lipid-laden plaque formation that 
characterized atherosclerotic aortas and carotid arteries. There was also a 
prominent inflammatory infiltration with mononuclear and foam cells in the 
atheromatous plaques. C pneumoniae  was stained dark brown within the  
macrophages/mononuclear cells in 12 of 20 atheromatous tissues, mainly 
atheromatous plaques (Fig.2). In the  atherosclerotic lesions, immunoreactivity 
for MMP-2, MMP-9, COX-2, EMMPRIN and MT1-MMP were evident in all 
cases along with plaques, primarily in macrophages/foam cells, intimal and 
medial smooth muscle cells, and endothelial cells of the intima. Within the 
intima, increased MMP-2, MMP-9, TIMP-2, EMMPRIN and  MT1-MMP 
immunoreactivities were found to have a similar pattern and distribution within 
the area stained by C pneumoniae (Fig.3).  
3.  Western blot 
Because EMMPRIN, MMPs, and TIMP share considerable homology, 
western blotting was performed to define the expression of these proteins 
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quantitatively and exclude cross reactivity by immunohistochemical staining. 
EMMPRIN, MMP-2 and TIMP-2 were more prominently detected in C 
pneumoniae infected atheromatous specimens than in control specimens (Fig. 
4).
 
4.  Gelatin zymography
In C pneumoniae  infected atheromatous specimens, a 92-kDa band 
corresponding to the activity of MMP-9 and  72-kDa band corresponding to 
the activity of MMP-2 demonstrated prominent comparing with weakly 
constitutive activity of  MMP-2 and non-induced activity of MMP-9 in control 
specimens quantitatively (Fig.5). Futhermore, gelatinolytic activity of MMP-2 
was more prominent than that of MMP-9 in C pneumoniae  infected 
atheromatous tissue  demonstrated similar patterns in western blot for 
EMMPRIN, MMP-2/TIMP-2, which are the upstream cellular and molecular 
mechanisms for a local MMP induction/activation system.
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IV. Discussion
Although it is tempting to consider C pneumoniae  infection as a possible 
primary cause of atherosclerotic lesion formation in some cases, the data 
currently available do not justify this conclusion. Infection of the vascular wall 
with C pneumoniae is generally focal and does not affect all lesions examined, 
raising legitimate questions about the specificity and the  biological significance 
of the detection of this agent within atheroma. However, a recent autopsy 
study showed greater frequency of chlamydial antigens in the cardiovascular 
tissues of patients who had died of ischemic heart disease than in those who 
died of noncardiac causes (64% versus 38%).  Moreover, the effects of a focal 
infection might influence the pathobiology of the surrounding atherosclerotic 
environment24. The present seroepidemiologic results demonstrate a positive 
correlation between C pneumoniae infection and ischemic heart disease, 
particularly in subgroups with few conventional coronary risk factors. 
Therefore, we can ascertain that C pneumoniae  may play a pathologic role in 
atherosclerosis in those with low risk. Furthermore, histopathological analysis 
demonstrated an abundance of C pneumoniae in macrophages/monocytes of the 
atheromatous plaques of aortas and carotid arteries obtained from cases who 
were defined as having seropositive C pneumoniae.
Many other seroepidemiologic and histologic results support an association 
between C pneumoniae  infection and atherosclerosis, but the pathogenic 
mechanism involved is not yet clear. Kreula et al. reported that chlamydial  
heat shock protein 60 induces the secretion of 92-kDa gelatinase (MMP-9) by 
human monocyte derived macrophages, and that C pneumoniae,  when present 
in a macrophage-containing inflammatory environment, actively participate in  
the destruction of the extracellular matrix19. Kol et al.  also suggested that 
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chlamydia induce the macrophage  production of TNF-α and MMPs18. 
In the present study, most of the cases showed increased expressions of 
MMP-2, MMP-9 and COX-2 where the immunoreactivity of C pneumoniae 
was abundant.   Immunoreactivity for MT1-MMP and TIMP-2 were found to 
have distributions similar to those of MMP-2 and MMP-9. In addition, gelatine 
zymography showed increased MMP-2 and MMP-9 activities in infected 
atheromatous tissues, this was more prominent for MMP-2. In spite of the 
possibility of an innocent bystander effect, these findings suggest that C 
pneumoniae might increase the capacity of macrophages to produce gelatinase 
(MMP-2 and MMP-9) by activating the expression of this enzyme. Such an 
increase in the expression of gelatinase could result in increased proteolytic 
activity in the microenvironment of the stimulated macrophages, and lead to 
enhance extracellular remodeling.  However, these results may contain 
somewhat limitations, for example, the present study did not include in vitro 
studies with  a pure infected monocytes/macrophage cell line, but rather to use 
inhomogenous atheromatous human tissues, and therfore many  factors other 
than C pneumoniae  infection, could have affected our results. However, despite 
these limitations, our results suggested that not only MMP-9 (92-kDa 
gelatinase) but also, MMP-2 (72-kDa gelatinase) might play an important role 
in the extracellular remodeling of C pneumoniae infected atheromatous tissues. 
MMP-2 and MMP-9 are commonly called gelatinases because of their high 
affinity for this substrate. Production of gelatinases by macrophages/monocytes 
has recently been observed in atherosclerotic aortic aneurysms, implying a 
potentially important role for these enzymes in atherosclerotic disease. COX-2 
is another enzyme regulated by NF-kB, is responsible for the increased 
production of prostaglandins and thromboxane in inflammatory disease. The 
induction of COX-2 in monocyte and the resulting production of prostaglandin  
E2 have been shown to be involved in the signal transduction pathway leading 
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to MMPs production in those cells. A possible pathophysiologic mechanism 
explaining these results is that the promoter region of the gene for gelatinase 
contains NF-kB binding sites, which play a critical role in the expression of 
this gene, therefore, the C pneumoniae-mediated effect on gelatinase (MMP-2, 
MMP-9) expression may be due to the activation of NF-kB. This possibility is 
supported by a recent observation that C pneumoniae  infection of vascular 
smooth muscle and endothelial cells activates NF-kB25.  The factors regulating 
the production of these MMPs in atherosclerotic lesions are not yet known. 
However, it is known that the activity of MMPs on substrates of the 
extracellular matrix depends on a balance between these enzymes and their 
endogenous inhibitors, the TIMPs. Since TIMP expression can be regulated by 
biological agents such as cytokines, we tested TIMP-2 expression on infected 
atheromatous tissue. Although TIMP-2 expression was observed by IHC of 
infected atheromatous tissue, its level was insignificant compared with other 
MMPs, and even its stimulated expression level was not high enough to 
achieve the 1:1 molar ratio required for full inhibition of gelatinase. 
However, it remains unclear whether the upstream cellular and molecular 
mechanism of local MMP induction/activation system actually exists. Recently,   
Spinale et al.21 demonstrated that MMP induction/activation system (EMMPRIN 
and MT1-MMP) exists in the human left ventricular myocardium and that this 
is upregulated in heart failure. Moreover Major et al.22 reported that EMMPRIN 
is induced on differentiating monocytes and is expressed in human atheroma. 
They suggested: 1) monocyte to macrophage differentiation induces both 
EMMPRIN and MMP expression;, and that 2) EMMPRIN may play a role in 
atherosclerotic lesion formation and that the influx/differentiation of monocyte 
may be responsible for potentially destabilizing atheroma. Through 
immunoprecipitation experiments, Berditchevski and colleagues26 demonstrated 
that EMMPRIN forms a complex with a3b1 integrin. The functions of integrins 
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include cell-cell adhesion, extracellular matrix-cell adhesion, and the 
transduction of cellular signaling cascades. The  coexistence of EMMPRIN and 
a3b1 integrin suggests that EMMPRIN mediated MMP induction may be 
influenced by both the composition and the level of stress placed on the 
extracellular matrix. The intracellular signaling pathways by which EMMPRIN 
facilitates MMP expression remain to be fully elucidated, but probably involve 
tyrosine kinase pathways. The EMMPRIN  protein sequence contains a PKC 
phosphorylation site, which may also be an important intracellular regulatory 
mechanism27. In vitro studies have demonstrated that although EMMPRIN 
induces MMP expression, it does not influence the basal expression of TIMP28. 
In the present study, a similar pattern of expression was observed in 
infected atheromatous tissue, in which increased EMMPRIN expression was 
associated with the increased expressions of MMP-2, and MMP-9, and 
minimal TIMP-2 expression. Thus, increased EMMPRIN expression in infected 
atheromatous tissues may contribute to increased MMP levels without a 
concomitant increase in TIMP expression, which in turn would ultimately favor 
matrix degradation and remodeling.  This provides circumstantial evidence that 
EMMPRIN may facilitate MMP-2 and MMP-9 expression in infected 
atherosclerotic plaques.
In conclusion, in this study we found that C pneumoniae  may be an 
independent risk factor of atherosclerosis. Moreover, C pneumoniae was 
abundant and colocalized with MMP-9, MMP-2 and EMMPRIN in the 
atheromatous plaques of infected patients.  Despite the possibility of innocent 
bystander effect, this finding suggests that C pneumoniae may play an 
important role in atherosclerosis and that a possible mechanism involve 
infected macrophage differentiation and the possible induction of MMP-2, and 
MMP-9 and the expression of EMMPRIN, and further that MMP-2 and 
MMP-9 participate in the degradation of the extracellular matrix component.
- 18 -
This study helps us to understand the molecular pathways by which allow 
C pneumoniae  to participate in atherogenesis and to explain the mechanisms of 
the epidemiologic and pharmacologic links between this infectious agent and 
the clinical  manifestations of atherosclerosis. Future studies involving 
EMMPRIN mediated MMP upstream regulation are necessary to fully elucidate 
the potential role of EMMPRIN in the progression of atherosclerosis.
- 19 -
V. Conclusion
The present study demonstrated that C pneumoniae  may be an independent 
risk factor of atherosclerosis. Moreover, C pneumoniae  was found to be 
abundant and to be colocalized with MMP-9, MMP-2 and EMMPRIN in the 
atheromatous plaques of infected patients. In spite of possibility of an innocent 
bystander effect, this finding suggests that C pneumoniae  plays an important 
role in atherosclerosis and that mechanism involves infected macrophage 
differentiation that induces MMP-2, MMP-9, COX-2 and expresses EMMPRIN, 
and that further MMP-2 and MMP-9 participate in the degradation of the 
extracellular matrix component.
We believe that the present study helps in the understanding of 
pathobiological effects by which C pneumoniae might participate in 
atherogenesis and to  explain the mechanism of the epidemiologic and 
pharmacologic links between this infectious agent and the clinical  
manifestations of atherosclerosis. Future study involving EMMPRIN mediated 
MMP upstream regulation is necessary to fully elucidate the potential role of 
EMMPRIN in the progression of atherosclerosis.
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국문 요약
동맥경화의 발생 및 진행에 있어 만성 
Chlamydia pneumoniae 감염의 역할
배경: 만성 Chlamydia pneumoniae 감염은 관상동맥 질환을 포함한 동맥경화의 
발생 및 진행의 중요한 위험인자임이 제시되고 있으며, 이러한 기전이 matrix 
metalloproteinase (MMP)룰 통해 이루어 진다는 여러 연구가 보고되고 있다. 그러
나 Chlamydia pneumoniae감염이 MMP의 발현과 활동을 조절하는 정확한 기전은 
밝혀져 있지 않으며, 단지 감염된 대식세포에서 분비되는 cytokine등 여러인자가 
작용한다고 알려져 있을 뿐이다. 최근 이러한 MMP를 유도하고 활성화 시키는 조
절인자인 EMMPRIN/MT1-MMP체계가 심근 및 동맥경화조직에서 발견되어 본 
실험에서는 혈청학적검사와 동맥경화 조직을 이용한 MMP, 
EMMPRIN/MT1-MMP의 면역검사를 통하여 C pneumoniae  감염이 동맥경화를 
진행시키는 기전을 알아보고자 하였다.   
대상 및 방법: 관상동맥질환을 가지고 있는 391명의 환자와 정상대조군 97명을 
대상으로 C pneumoniae감염의 혈청학적 양성률을 측정하였으며, 혈청학적으로 C 
pneumoniae 항체 양성이며  동맥경화성 대동맥류와 경동맥 협착증이 있는 20명
의  환자에서 얻은 동맥경화 조직을 대상으로 C pneumoniae, MMP-2, MMP-9, 
TIMP-2, EMMPRIN/MT1-MMP 의 면역형광염색과 western blot, gelatine 
zymography를 시행하였다.
결과:관상동맥질환을 가진 환자에서 대조군보다 높은 C pneumoniae 항체 양성률
을 보였으며, 특히 일반적인 동맥경화의 위험인자를 가지지 않은 군에서 위험인자
를 가진군보다 항체 양성률이 높았다. 또한 20명의 동맥경화조직중 12명의 조직에
서 C pneumoniae를 확인할수 있었으며, C pneumoniae가 존재하는 대식세포 주
위로 MMP-2, MMP-9, EMMPRIN의 표현이 증가되어 있으며, 정상대조군에 비
해 MMP-2 와 MMP-9의 활성화도 증가되어 있는 것을 확인 할 수 있었다.
결론: 만성 C pneumoniae감염은 동맥경화증 진행에 중요한 역할을 함을 알 수 
있었으며. 그 기전에 MMP 및 그 조절인자인 EMMPRIN/MT1-MMP 체계가 관
여함을 알 수 있었다.
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
핵심되는 말: 만성 Chlamydia pneumoniae  감염, 동맥경화증, MMP, EMMPRIN
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Table 1. Seropositive rate of Ig G andIgA antibodies against Chlamydia pneumoniae.
Antibodies        Group I         Group II         Group III
p-value
Group I vs II      Group I vs III      Group II vs III      Group I+II vs III   
IgG              59.8%           67.2%             47.4%         NS                 0.041      0.004              0.010 
IgA              64.6%           74.5%             57.7%         NS                  NS 0.011                NS
IgG & A          56.7%           61.3%             43.3%         NS                0.033             0.010              0.011   
X2test; NS, not significant (p > 0.05).
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Table 2.  Seropositive rates of Ig G and Ig A antibodies in Group I and III, subgrouped by known risk factors of CAD.
risk factor
Seropositivity (%)
Group I          Group III
p-value     OR(95% CI) Adjusted OR(95% CI) 
Age(year) ≥55                       62.5             53.3              NS
< 55                       38.7             38.8 NS
Male                                     59.4             52.7                NS
Female                                  52.1             31.0              0.035           2.4          5.2
Smoker                                  59.3             56.5   NS 
Nonsmoker                             54.4             31.4     0.008           2.6                  3.9
Hypertension                          52.3              46.7    NS
Normotensive 61.5              42.7              0.013           2.1 
Diabetes                                47.8              70.0  NS
Non-diabetes                         59.9              40.2         0.004           2.2 
T-chol(mg/dl) ≥240               35.0              53.3               NS
< 240               58.6             41.5 0.016           2.0
HDL-chol(mg/dl) ≤35             57.6             55.6               NS
> 35            58.1              42.0 0.038           1.9
LDL-chol(mg/dl) ≥160            52.6             56.3               NS
< 160            58.3              40.7 0.018          2.0
X2 test; logistic regression test; NS, not significant (p > 0.05); OR, odds ratio
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C p  x  2 0 0
F ig . 1 . H em a toxy lin &  E os in  s ta in , im m unochem is try fo r M M P -2 , M M P - 9 , T IM P- 2 , E M M P R IN  and  C h lam yd ia  pneum on iae
A b .  S e c t io n s  o f  a o r ta  ta k e n  f ro m  t ra u m a tic  d is sec tio n  w ith  C p neu m o n ia e seo ro nega tiv ity sh o w s   no  s ig n if ic a n t
h is to log ica l ev idence  o f a th e rosc le ros is . N o   im m uno reac tiv ity  fo r an ti- C pneum on iae  A b , M M P- 2 , M M P - 9 , T IM P-2  and
trace  im m uno reac tiv ity fo r E M M P R IN  (rec tang le ) a re  show n .  (C p ; pneum on iae ) 
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A. C.Pneumoniae x100 B. C.Pneumoniae x1000
C. MMP-9 x400 D. TIMP-2x100 TIMP-2x400
plaque
B. C pneumoniae x 1000
COX-2x400
Fig. 2. Intracelluar C pneueumoniae are distributed in the base of atherosclerotic plaque (panel A,
x100) and the immunoreactivity  to  C  pneumoniae is  primarily located in the macrophage/
mononuclear cells (panel B). The small  box in panel B indicates the macrophage-rich region 
sampled from panel A and put into a high power view to define  colocalization  between
intracellular C pneumoniae  and tissue macrophage/mononuclear  cells (small  box  in   panel B,  
x 400, immunostaining  with HAM56). The  arrow  in  panel B  indicates  macrophages (HAM 56+)  
that  are  stained positively  to  C pneumoniae.   Expression  of  MMP-9  (panel C),  COX-2  
(small  box  in panel C, x400), and TIMP-2 (panel D)  show  clocalization  of immunoreactivity  
between C pneumoniae, COX-2, MMP-9 and its inhibitor (TIMP-2).
A. C pneumoniae x100
HAM 56 x 400
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Cp x 200 Cp x 400 TIMP-2 x 1000
Fig. 3.  Hematoxylin  &  Eosin  stain  of  atheromatous  plaque  of carotid artery obtained from C pneumoniae
seropositive patient shows prominent  inflammatory infiltration  with  mononuclear cell  and foam cells 
(panel A). In  the same  area with panel A, increased  EMMPRIN, MMP-2,  MMP-9  and  MT1-MMP 
Immunoreactivities (dark brown color) are found in a similar pattern and distribution (panel B-F, Mφ; 
macrophage) with the area stained by C pneumoniae (panel G & H, arrowhead, Cp ; C pneumoniae). Put into a 
high power view of small box in panel H shows immunoreacticity of TIMP-2 (panel I).
A B C
D E F
G H I
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A1         A2     A3       C1  C2 C3
EMMPRIN
MMP-2
TIMP-2
A1, A2, A3; Carotid Atheroma
C1, C2, C3; Control Aorta
Fig. 4. Western blot for EMMPRIN, MMP-2, TIMP-2.  EMMPRIN, MMP-2 and TIMP-2 are detected 
more prominent in C pneumoniae infected atheromatous tissues compared with control tissues. 
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Marker  A1  A2  A3  C1  C2 C3    
92-kDa
72-kDa
A1, A2, A3; Carotid Atheroma
C1, C2, C3; Control Aorta
Fig. 5.  Gelatine zymography for detection of MMP-9 and MMP-2 in infected atheromatous
plaques. A 72-kDa band corresponding to MMP-2 and fainter 92-kDa band correponding to
MMP-9 appeared in C pneumoniae infected atheromatous plaques. Gelatinolytic activity of 
MMP-2 is more prominent than that of MMP-9. But weak or no gelatinolytic activity is seen
in control data. 
